Copyright
©The Author(s) 1997.
World J Gastroenterol. Mar 15, 1997; 3(1): 43-46
Published online Mar 15, 1997. doi: 10.3748/wjg.v3.i1.43
Published online Mar 15, 1997. doi: 10.3748/wjg.v3.i1.43
Figure 1 Electron microscope observation of resected specimen 125I anti alpha fetoprotein treatment.
(Li, male, 27 years old, HCC, admittance No.10206 tumor cross section, necrotic material, capsule intact electron microscope: Degeneration, necrosis of tumor tissue). Normal liver cell, from juxta tumor. × 2200
Figure 2 Electron microscope observation of resected specimen 125I anti alpha fetoprotein treatment.
(Li, male, 27 years old, HCC, admittance No.10206 tumor cross section, necrotic material, capsule intact electron microscope: Degeneration, necrosis of tumor tissue). Dissolution of nucleus. × 7700
Figure 3 Electron microscope observation of resected specimen 125I anti alpha fetoprotein treatment.
(Li, male, 27 years old, HCC, admittance No.10206 tumor cross section, necrotic material, capsule intact EM: Degeneration, necrosis of tumor tissue). Nuclear dissolution, organelle vacuolation. × 4000
Figure 4 Electron microscope observation of resected specimen 125I anti alpha fetoprotein treatment.
(Li, male, 27 years old, HCC, admittance No.10206 tumor cross section, necrotic material, capsule intact EM: Degeneration, necrosis of tumor tissue). Pyknotic nucleus, organelle vacuolation. × 7700
- Citation: Wu YD, Yang KZ, Zhou DN, Gang YQ, Song XQ, Hu XH, Huang BY. Clinical observation of 125I-labeled anti-alpha fetoprotein antibody radioimmunotherapy in hepatocellular carcinoma. World J Gastroenterol 1997; 3(1): 43-46
- URL: https://www.wjgnet.com/1007-9327/full/v3/i1/43.htm
- DOI: https://dx.doi.org/10.3748/wjg.v3.i1.43